Product logins

Find logins to all Clarivate products below.


Digital Marketing in 2015: Why and How Pharma Must Harness a More Strategic Approach

For digital marketing to truly deliver on its potential, most pharmas have to face and fix four interrelated issues. The first has to do with reforming the organizational structure of marketing and sales to empower digital as a primary, not ancillary, channel. The next two issues underpin the first, namely developing robust, marketing-related analytics and moving to better funding of digital. The fourth issue, and the topic of this report, is the need for digital teams and brands overall to shift from an adolescent tactic-based marketing approach to a more-mature strategic approach centered on the customer experience. Vanguard companies taking a more holistic approach to developing strategy consider customer pain points and needs along the treatment journey, along with digital audits and competitive reviews in the process, all within the context of overarching brand goals. The remaining companies are either still tactically focused and media-specific or reliant on customer digital insights alone. This report makes a case for why digital marketers need to embrace a more-robust strategic approach to multichannel marketing and includes hypothetical digital strategic plans for rheumatoid arthritis and Crohn’s disease.

Related Market Assessment Reports

Report
Hemophilia A – Current Treatment – Current Treatment: Physician Insights – Hemophilia A with Inhibitors (US)
Development of neutralizing antibodies against factor VIII replacement is the most significant clinical complication in hemophilia A, necessitating specialized and often high-cost management…
Report
Major Depressive Disorder (DSM-V) – Access & Reimbursement – Access & Reimbursement – Major Depressive Disorder (US)
Numerous drugs from multiple drug classes are used as monotherapies and/or adjunctive therapies to treat major depressive disorder (MDD). Early-line treatment is dominated by generically available…
Report
Malignant Melanoma – Unmet Need – Unmet Need – BRAF Wild-Type, Unresectable or Metastatic Malignant Melanoma (US/EU)
Treatment for BRAF wild-type unresectable or metastatic melanoma has been largely shaped by the successive approvals of immune checkpoint inhibitors. Anti-PD-1 agents such as Keytruda (Merck & Co…
Report
Systemic Lupus Erythematosus | Unmet Need | Moderate to Severe Systemic Lupus Erythematosus | US/EU | 2024
Systemic lupus erythematosus (SLE) is an autoimmune disease that can affect different organ systems of the body and manifest in a wide range of clinical symptoms, from general fatigue to serious…
Report
Systemic Lupus Erythematosus – Unmet Need – Unmet Need – Moderate to Severe Systemic Lupus Erythematosus (US/EU)
Systemic lupus erythematosus (SLE) is an autoimmune disease that can affect different organ systems of the body and manifest in a wide range of clinical symptoms, from general fatigue to serious…